文献速递类风湿关节炎

患者活动量表II最小临床重要变化值的定义

Defining Minimum Clinically Important Changes for the Patient Activity Scale II.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-08-20

本研究基于Forward databank四个6个月数据收集期,采用锚定法和分布法估算PAS-II(范围0-10)的最小临床重要改善(MCII)与恶化(MCIW)。总体样本中锚定法MCIW约0.50-0.55、MCII约0.39-0.45,按基线评分分层后低疾病活动者MCIW约1.1、中高活动者MCII约1.1,接受新治疗者达到MCII的比值比高30%。

要点

  • 总体PAS-II最小重要变化约0.5分。
  • 基线中高活动度者MCII约1.1分,低活动度者MCIW约1.1分。
  • 接受新治疗者达到MCII的比值比高30%。

核心结论

  • PAS-II的最小重要变化约为0.5分。
  • 中高PAS-II评分者MCII为1.1,低疾病活动者MCIW为1.1。

研究设计与样本

  • 数据取自Forward(美国风湿病国家数据库)四个6个月数据收集期。
  • 采用锚定法与分布法(0.5和0.35 SD)估算MCII与MCIW。
  • 按PAS-II评分高于/低于3.7分层分析。

主要发现

  • 总体样本锚定法(疼痛/总体健康)MCIW为0.50和0.55。
  • 总体样本锚定法(疼痛/总体健康)MCII为0.39和0.45。
  • 低疾病活动者锚定法MCIW为1.10(疼痛/总体健康1.09/1.11)。
  • 中高疾病活动者锚定法MCII为1.09(疼痛/总体健康1.15/1.02)。
  • 分布法0.5和0.35 SD对应值为1.08和0.76。

关键数值与推荐

  • PAS-II评分范围为0-10。
  • 分层阈值为PAS-II评分3.7。
  • 锚定问题比较疼痛和总体健康与过去6个月的变化。
  • 接受新治疗者达到MCII的比值比高30%。

临床怎么用

  • 可将PAS-II变化约0.5分作为总体最小重要变化参考。
  • 对中高活动度患者,改善约1.1分可视为临床重要改善。
  • 对低疾病活动度患者,恶化约1.1分可视为临床重要恶化。

局限性

  • 数据来自Forward数据库四个6个月收集期,未报告样本量。
  • 锚定法仅基于疼痛与总体健康两个锚定问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define the minimum clinically important improvement (MCII) and minimum clinically important worsening (MCIW) for the Patient Activity Scale II (PAS-II; range 0-10), a recommended patient-reported outcome measuring rheumatoid arthritis disease activity. METHODS: Data were taken from Forward, The National Databank for Rheumatic Diseases, from four 6-month data collection periods. Both anchor-based and distribution-based methods were used to estimate the MCII and MCIW. Anchor-based analyses used comparisons of pain and general health to the previous 6 months. Distribution-based analyses used 0.5 and 0.35 SDs. We stratified analyses based on the PAS-II score (above/below 3.7), hypothesizing that the MCII and MCIW would depend on the baseline score. To assess construct validity, we evaluated the odds of achieving the MCII in patients receiving new therapies. RESULTS: In the overall sample, for pain and general health anchor questions, the MCIW was 0.50 and 0.55, respectively. The MCII was defined as 0.39 and 0.45, respectively, for pain and general health. The MCIW for anchor-based methods among participants with low disease activity was 1.10 (1.09/1.11 [pain/general health]), while the MCII for those with moderate-to-high disease activity was 1.09 (1.15/1.02 [pain/general health]). Distribution-based methods for 0.5 and 0.35 SD were 1.08 and 0.76, respectively, for pain and general health. There was fair-to-excellent agreement with clinically important differences in assessments of pain and disability. Patients receiving new treatments had 30% greater odds of achieving the MCII. CONCLUSION: The minimum important change in PAS-II score was approximately 0.5. Among participants with a moderate-to-high PAS-II score , the MCII was 1.1, and among participants with low disease activity, the MCIW was 1.1.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Baker JF, Katz P, Michaud K, et al. Defining Minimum Clinically Important Changes for the Patient Activity Scale II. Arthritis Care Res (Hoboken). 2021. PMID: 32475071. doi:10.1002/acr.24335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。